Table 2 Immune-related adverse events (n = 20)

From: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

 

Number of patients with event (%)

Grade 1

Grade 2

Grade 3

Any immune-related adverse event

9 (45%)

7 (35%)

2 (10%)

Infusion-related reaction

2 (10%)

3 (15%)

Fatigue

4 (20%)

Fever

4 (20%)

Arthralgia

1 (5%)

1 (5%)

Hypothyroidism

1 (5%)

1 (5%)

Diarrhea

1 (5%)

Headache

1 (5%)

Hepatitis

1 (5%)

Photosensitivity

1 (5%)

Rash maculopapular

1 (5%)

  1. All AEs that were deemed at least possibly related to atezolizumab are shown in this table. This is regardless of the possible relationship with chemotherapy.